Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Buy” by Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.20.

A number of research analysts have recently commented on GANX shares. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a report on Monday, March 17th. Chardan Capital reissued a “buy” rating and issued a $6.00 price target on shares of Gain Therapeutics in a research report on Friday. Scotiabank initiated coverage on shares of Gain Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $12.00 price objective for the company. Roth Capital upgraded shares of Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Finally, Roth Mkm restated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a report on Tuesday, December 24th.

Gain Therapeutics Trading Up 1.1 %

Shares of NASDAQ GANX opened at $1.91 on Tuesday. The business has a 50 day simple moving average of $2.21 and a 200 day simple moving average of $2.07. Gain Therapeutics has a 52 week low of $0.89 and a 52 week high of $4.04. The stock has a market cap of $50.66 million, a price-to-earnings ratio of -1.74 and a beta of 0.14. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.07. On average, research analysts predict that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Gain Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Jones Financial Companies Lllp grew its holdings in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after purchasing an additional 44,750 shares in the last quarter. Geode Capital Management LLC lifted its position in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares during the period. Benedict Financial Advisors Inc. bought a new stake in Gain Therapeutics in the 4th quarter valued at $35,000. Sprott Inc. acquired a new position in shares of Gain Therapeutics in the 4th quarter valued at $30,000. Finally, Northern Trust Corp raised its stake in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares in the last quarter. 11.97% of the stock is owned by institutional investors and hedge funds.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.